Q-omics provides the consensus-scored FAM9A profile across patient tissues and cancer cell-line models. FAM9A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM9A is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, FAM9A RNA expression shows 11,094 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where FAM9A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM9A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM9A survival associations across molecular data types. FAM9A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM9A RNA expression–survival associations across cancer types. High FAM9A expression shows unfavorable associations in ACC, STAD, KIRC, KICH, BLCA and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM9A RNA expression.
This table summarizes FAM9A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM9A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM9A shows lower tumor expression in CHOL and higher tumor expression in KIRC, COAD, BRCA, STAD and LUSC. The KIRC box plot shows higher FAM9A RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p < 0.001).
This table shows molecular features associated with FAM9A in patient tissues and cancer cell lines. In patient samples, FAM9A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM9A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_NSCLC_LUSC.
